The European Union's long-awaited reform of its pharmaceutical legislation has been heralded as a breakthrough for competitiveness, innovation, and critically, for patient access.
Given the structural challenges that have shaped Europe's medicines landscape for more than two decades, the reform indeed marks an important milestone. Yet its ultimate success will depend not merely on legislative ambition but on the capacity of policymakers, regulators, and industry to implement it with a shared commitment to equity across all member states.
For smaller markets, the stakes could not be higher. Europe has long struggled with disparities in the availability of new treatments, with patients in larger member states regularly gaining access many months, and in some cases years, ahead of those in the bloc's periphery.
These delays are often the product of fragmented pricing systems, administrative bottlenecks, and commercial decisions that prioritise higher-volume markets. The result is a quiet divergence in patient outcomes within a Union that aspires to cohesion.
Such differences are rarely acknowledged in political rhetoric, yet they are deeply felt by healthcare professionals and patients in smaller states, including Malta.
As a pharmaceutical distributor that operates exclusively within such an environment, Vivian witnesses the human consequences of these gaps daily. For a person living with a rare disease, a paediatric condition, or a rapidly progressing form of cancer, a regulatory delay is not an abstract policy flaw; it is a lived constraint on one's prospects for survival and quality of life.
The recent legislative overhaul attempts to confront this challenge more directly. By linking certain incentives to broader and more timely market launches, by reinforcing obligations on supply continuity, and by defining clearer pathways for unmet medical needs, the EU is signalling an intention to rebalance the equation.
But legislation, however sophisticated, cannot account for every operational or market-specific nuance. Implementation will require discipline, collaboration, and a willingness among all actors to accept that equitable access is a strategic imperative, not merely an ethical aspiration.
It is with this premise that Path - Promoting Access to Treatments & Healthcare - was established as a think tank developed together with international partners, dedicated to contributing practical proposals to advance access across Europe.
Its work focuses on three pillars: accelerating availability of treatments for unmet needs, ensuring fair and timely access irrespective of market size, and strengthening the resilience of supply chains.
These priorities align closely with the objectives of the EU reform, but they also reflect realities that may not be fully addressed by legislation alone.
Rare diseases and paediatric populations, for instance, continue to suffer from structural under-investment globally, and Europe must ensure that regulatory efficiency is matched by commercial viability. Similarly, access for smaller member states requires more than legal incentives; it demands transparency from industry, responsiveness from regulators, policymakers, and cross-border cooperation among national authorities.
In supply resilience, the EU's intentions are clear, but achieving true continuity will depend on rebuilding the strategic autonomy that Europe has gradually ceded.
Recent shortages have demonstrated how vulnerable European patients are to disruptions far beyond the continent's control. Strengthening resilience will require diversified production, improved forecasting, and a more strategic approach to stock management. These steps must involve both private operators and national systems.
The question now is whether Europe can convert legislative design into measurable improvement and in this environment, companies must demonstrate more than compliance. They must show an active commitment to the principles underpinning the reform.
For pharma companies like ours, this means continuing to invest in quality systems, maintaining rigorous compliance standards, and championing the interests of Maltese patients, who deserve access comparable to that of any European citizen.
Europe's pharmaceutical reform provides a stronger foundation than the fragmented framework it replaces. It represents significant progress but not completion. To translate policy into patient benefit, Europe will need to embrace the spirit of collective responsibility that the legislation implies.
If Europe succeeds, it will not only bolster its competitiveness but reaffirm its commitment to the citizens who depend on its healthcare systems most.
Corinne Zaffarese Elbourne is Regulatory Affairs and Quality Unit manager
at pharma and wellbeing company Vivian